Name | YYA-021 |
Synonyms | YYA-021 CS-2313 YYA-021 (YYA 021 N1-(2,2,6,6-tetraMethylpiperidin-4-yl)-N2-p-tolyloxalaMide N-(2,2,6,6-Tetramethyl-piperidin-4-yl)-N'-p-tolyl-oxalamide N-(4-Methylphenyl)-N'-(2,2,6,6-tetramethylpiperidin-4-yl)oxalamide N1-(4-Methylphenyl)-N2-(2,2,6,6-tetramethyl-4-piperidinyl)ethanediamide Ethanediamide, N1-(4-methylphenyl)-N2-(2,2,6,6-tetramethyl-4-piperidinyl)- |
CAS | 144217-65-2 |
Molecular Formula | C18H27N3O2 |
Molar Mass | 317.43 |
Density | 1.11±0.1 g/cm3(Predicted) |
Solubility | 10 mM in DMSO |
pKa | 11.61±0.70(Predicted) |
Storage Condition | -20℃ |
In vitro study | YYA-021 enhance the neutralization susceptibility of apes-human immunodeficiency virus (HIV-1) carrying MNA envelope isolated from clade B clinical human immunodeficiency virus type I (SHIV). |
In vivo study | In rats and rhesus monkeys, YYA-021 (I. V.) has a moderate Half-Life, broad tissue distribution, and relatively high volume distribution. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.15 ml | 15.752 ml | 31.503 ml |
5 mM | 0.63 ml | 3.15 ml | 6.301 ml |
10 mM | 0.315 ml | 1.575 ml | 3.15 ml |
5 mM | 0.063 ml | 0.315 ml | 0.63 ml |
biological activity | YYA-021 is an HIV entry inhibitor that mimics CD4, competitively inhibiting the interaction between gp120 and CD4. |
Target | Value |